pis...(put something here)
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Nice bounce on VFC today
I really don't know much about the Expert Market. I don't trade pennies anymore. But I have about three bagholds from way back when and this co is one of those. I must have signed up years ago for filing alerts on this co. Every time they file I get an email that alerts me.
SC 13D/A 11/01/2023 filed
VFC down another buck after earnings miss yesterday and had it dive
WE down 51% on bk fears
KTRA down 79% failure of the company's lead product
8k filed today:
Note: “We”, “Us”, “The Issuer”, and or “The Company” refer to Next Meats Holdings, Inc., a Nevada Company.
Item 3.02 Unregistered Sales of Equity Securities.
On or about September 7, 2023, the Company entered into an agreement for the purchase of 40,168,092 shares of the Company’s restricted Common Stock from Ryo Shirai, a Japanese Citizen and our former Chief Executive Officer, at a price of $0.001 per share of Common Stock. The transaction was completed, and recorded, by the Company’s transfer agent on October 23, 2023, at which time the 40,168,092 resumed the status of Treasury Shares. The total subscription amount paid by the Company was approximately $40,168. At this time, Ryo Shirai is not a related party to the Company.
The aforementioned sale of shares was conducted pursuant to Regulation S of the Securities Act of 1933, as amended ("Regulation S"). The sale of shares was made only to non-U.S. persons/entities (as defined under Rule 902 section (k)(2)(i) of Regulation S), pursuant to offshore transactions, and no directed selling efforts were made in the United States by the issuer, a distributor, any of their respective affiliates, or any person acting on behalf of any of the foregoing.
Following the sale of restricted common shares to the Company, we now have 462,705,290 shares of Common Stock issued and outstanding as of the date of this report.
Item 9.01 Financial Statements and Exhibits.
None.
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Next Meats Holdings, Inc.
Dated: October 31, 2023
By: /s/ Koichi Ishizuka
Koichi Ishizuka,
Chief Executive Officer
Flipped that one yesterday and bought it back again this morning on the dip and flipped it again.
The end of year does make the wash sale a tricky situation. I trade actively and don't let wash sales stop me. Years ago it was a different situation because the brokerages didn't have to report cost basis and wash sales and you were solely responsible for keeping track of wash sales. There actually was a software you could buy to keep track of them - don't quote me but maybe it was gainskeeper? But it is way easier nowadays.
Not really. The wash sale was created to stop people from using it as a way of taking a loss on something that they still want to own. And when they don't allow the loss because you rebought it within the wash-sale time period, they are still allowing you to take that loss but on a delayed basis. They add the loss that you weren't allowed to take to the cost basis of the new shares you bought. So basically you are still taking that loss but later on.
PETS down 29% loss in the second quarter and suspended its divy
Yeah, that's what I would do. So technically they are worthless to you, but they aren't really worthless unless they no longer trade because you can still sell them. That's better for you. I really don't recall what other brokers do in this case. It's been so long since I traded otc's. But I hear you on the Etrade rant. Morgan Stanley has ruined that brokerage. They used to be so much more customer friendly to active traders. Now they nickel and dime you for everything.
Now down 41% - I'll take some here lol
COMM down 22% issues downside guidance
Haven't touched that one and for the exact reason you brought up. The volume stinks.
What would be the point of paying $5 to get rid of a "worthless" security?
-Well, I could think of a few. One that you brought up. If they are penny stocks that you have held for many years the chance of them reversing again and hitting you with another reorg fee are possible. Wouldn't you rather pay $5 to get rid of them then chance a $38 fee down the line? Why can't you just sell them online yourself instead of having Etrade do it? The way it used to work was (and I point this out because they have changed so many rules since MS took them over) if say you sell the entire position, they only charge a commission up to what it was worth. So if your entire position only comes to $3 but you pay $5 commission, they just charge the commission at $3.
-Not sure if theses stocks are actually "worthless." If they are still trading and doing reorg like reverse splits then they are not considered worthless. You could clean up your account and have a nice loss to offset your gains so you don't have to pay any taxes on them. If those losses exceed your gains you can use them each year as a carry over to offset future gains as long as your bottom line doesn't exceed a negative 3k for the year.
If they are truly "worthless" and they are listed under a cusip number you technically need to rid of them the year they officially became worthless. If you didn't do that in the year they became worthless you could always go back and do an amended return - I think you have up to seven years to do that.
Going back to pre MS, I have in the past removed stocks that were listed in my port as a cusip. I thought they would be considered worthless but Etrade figured them in as a total loss on my 1099. Maybe a stock isn't considered totally worthless even when it is under a cusip.
I'm guessing from your description that your stocks aren't truly "worthless" and you can easily use them as a tax loss. Unless you are still following them and you think there is a future event that may catapult them why bother keeping them?
VVOS down 42% after reverse splitting today 1:25
AIRE holy cow Batman - geez, ipo that keeps dropping after huge first day
SGHT Item?7.01
Regulation FD Disclosure
Sight Sciences, Inc. (the “Company”) is evaluating its guidance for full year 2023 due to the uncertain impact of reimbursement coverage for its Surgical Glaucoma segment discussed below. The Company plans to discuss any updates to its guidance on its upcoming earnings conference call currently scheduled to be held on November 7, 2023.*
Sorry to hear - hope you feel better
SGHT down 50% don't see anything yet
SONN down 36% offering priced at $1.60
NUZE down 40% offering priced at 3
EVLO down 55% Evelo Biosciences said it is reviewing strategic alternatives after its Phase 2 clinical trial of EDP2939 for the treatment of moderate psoriasis failed to meet its primary endpoint.
MANU down 11% Qatari banker Sheikh Jassim is withdrawing his bid to buy Manchester United
BIOC down 59% After considering strategic alternatives, Biocept, Inc., a Delaware corporation (the “Company”), filed a voluntary petition for relief (the “Petition”) under the provisions of Chapter 7 of Title 11 of the United States Code, 11 U.S.C. §§ 101 et seq. (the “Code”) in the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on October 13, 2023.
OMER down 46% Omeros said it is discontinuing its late-stage clinical trial evaluating its narsoplimab drug for the treatment of immunoglobulin A nephropathy after interim data from the trial failed to meet its primary endpoint.
ALDX down 73% The FDA stated that "t does not appear that you have data to support the clinical relevance of the ocular signs to support your dry eye indication."
OM down 50% reported lower-than-expected preliminary third-quarter revenue and warned of lower capital spending in the fourth quarter.
PHIO down 41% after huge run yesterday when they reported favorable data from two preclinical studies
HOFV down 29% offering priced at 3.75
SILK down 50% lowered its full-year revenue outlook
I flipped it for a buck gain. - edit actually for a 1.32 gain - should have held it longer I would have been up four bucks.
AKRO down 68% the company released an update on its lead product candidate, a treatment for nonalcoholic steatohepatitis, a form of fatty liver disease.
To add insult to injury SEEL has an offering the day after they huge drop. Priced at .30. Down another 34% today.
Ok, I finally dipped in and got some ARM - hope I want them.
SEEL down 76% - too small sample size means the study did not meet its primary end point
Yes, I have been watching it.
Sold that one way too early at 2.88 - nice bounce.
SPRY down 59% after FDA responce